A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
- 13 February 2021
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 397 (10275), 695-703
- https://doi.org/10.1016/s0140-6736(21)00152-5
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Cancer Institute (CA180819, CA180820, CA180821, CA180863, CA180868, CA180888)
- Wayne State University
This publication has 27 references indexed in Scilit:
- Comprehensive Molecular Characterization of Papillary Renal-Cell CarcinomaThe New England Journal of Medicine, 2016
- Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinomaBritish Journal of Cancer, 2015
- First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)Annals of Oncology, 2015
- Volitinib, a potent and highly selective c‐Met inhibitor, effectively blocks c‐Met signaling and growth in c‐MET amplified gastric cancer patient‐derived tumor xenograft modelsMolecular Oncology, 2014
- MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression ArrayClinical Cancer Research, 2014
- The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal NeoplasiaThe American Journal of Surgical Pathology, 2013
- Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell CarcinomaJournal of Clinical Oncology, 2013
- A Phase 2 Trial of Sunitinib in Patients with Advanced Non–clear Cell Renal Cell CarcinomaEuropean Urology, 2012
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor GrowthMolecular Cancer Therapeutics, 2011
- An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic MechanismsCancer Research, 2007